GlassScriptPhysician profile
Grace J Stonerock
NPI 1629234489
$18,124.36
in general payments reported to CMS, 2019-2025
47 companies · $3,364 in 2025
The $3,364 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,887 · 2020: $2,102 · 2021: $2,607 · 2022: $2,680 · 2023: $2,498 · 2024: $2,987 · 2025: $3,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,726 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,725.66 |
| Education | $122.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,821.85 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $2,391.77 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,545.94 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $1,316.23 | 2019-2025 | |
| Lilly USA, LLC | $1,091.26 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $977.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $936.43 | 2019-2023 | |
| Amgen INC. | $850.00 | 2019-2025 | Otezla, Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $601.74 | 2019-2025 | Trintellix, Gattex |
| Otsuka America Pharmaceutical, INC. | $513.46 | 2021-2025 | Rexulti |
| Amarin Pharma, INC. | $394.35 | 2019-2022 | |
| Verona Pharma, INC. | $392.58 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $372.72 | 2022-2025 | |
| Astellas Pharma US INC | $340.65 | 2019-2025 | Veozah, Myrbetriq |
| Currax Pharmaceuticals LLC | $295.06 | 2019-2023 | Contrave, Onzetra Xsail, Nexlizet |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Stonerock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.